Guardant Health wins European CE mark for Guardant360 CDx
Guardant Health secured a European CE mark for Guardant360 CDx and will release third-quarter 2026 results on November 5.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
TradingView reports that Guardant Health received a CE mark in Europe for Guardant360 CDx. The test is authorized as a companion diagnostic to detect ESR1 mutations in patients with ER+, HER2− advanced or metastatic breast cancer and help guide treatment with camizestrant.
Guardant Health is scheduled to publish its third-quarter 2026 results after the market close on November 5, 2026. The company will also hold a webcast that day to discuss the figures, beginning at 1:30 p.m. PT and 4:30 p.m. ET.
Guardant Health was also named among biotechnology companies purchased by ARKG. According to TradingView, the transaction formed part of ARKG’s broader accumulation of positions in genomics and biotechnology companies.
why it matters
The European marking adds regulatory recognition for Guardant360 CDx, while the scheduled results release may draw attention to GH. ARKG’s purchase also highlights fund interest in the company and genomics-related holdings.
instruments
sources
- Weekly Recap: CE marking for Guardant360 CDx and Q3 2026 results webcast — TradingView, 12 October 2026 at 11:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗